Mosaic ImmunoEngineering Inc. (CPMV) Form 10-Q — May 20, 2026
Mosaic ImmunoEngineering reported a net loss of $175,351 for the quarter ended March 31, 2026, with cash and cash equivalents dwindling to just $72. The company has no revenue and faces substantial doubt regarding its ability to continue as a going concern, explicitly stating that current cash will not satisfy operational requirements for the next twelve months. The balance sheet reveals a stockholders' deficit of $7.65 million, driven by $4.37 million in accrued compensation and $1.48 million in convertible notes.
Key figures
- Total Assets
- 9828
- Cash Position
- 72
- Shares Outstanding
- 7242137
- Loan Payable
- 200000
- Accrued Compensation
- 4370369
- Convertible Notes Net
- 1483929
- Total Current Liabilities
- 6177270
Price after filing
Close on the filing date to close N calendar days later (from $0.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.